|1.||Mehta, Minesh P: 13 articles (11/2011 - 08/2002)|
|2.||Miller, Richard A: 11 articles (12/2009 - 08/2002)|
|3.||Magda, Darren: 7 articles (11/2013 - 04/2004)|
|4.||Khuntia, Deepak: 6 articles (02/2011 - 12/2004)|
|5.||Phan, See-Chun: 6 articles (12/2009 - 07/2003)|
|6.||Renschler, Markus F: 6 articles (03/2009 - 08/2002)|
|7.||Evens, Andrew M: 5 articles (04/2010 - 11/2004)|
|8.||Naumovski, Louie: 5 articles (12/2009 - 12/2005)|
|9.||Gordon, Leo I: 4 articles (04/2010 - 02/2005)|
|10.||Smith, Jennifer A: 4 articles (03/2009 - 08/2002)|
|1.||Neoplasm Metastasis (Metastasis)
02/01/2011 - "Motexafin gadolinium is a novel radiosensitizer with clearly documented efficacy, particularly in patients with brain metastases. "
11/01/2011 - "Safety and feasibility of motexafin gadolinium administration with whole brain radiation therapy and stereotactic radiosurgery boost in the treatment of ≤ 6 brain metastases: a multi-institutional phase II trial."
12/01/2007 - "The radiation sensitizing properties of Motexafin gadolinium (MGd) have been investigated in a number of clinical trials involving patients with brain metastases. "
01/01/2004 - "Pharmacyclics has completed enrollment and follow-up of adults in its pivotal phase III trial of motexafin gadolinium as a radiation sensitiser for the treatment of brain metastases. "
01/01/2004 - "Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial."
02/13/2009 - "Motexafin gadolinium (MGd) is an expanded porphyrin anticancer agent which selectively targets tumor cells and works as a radiation enhancer, with promising results in clinical trials. "
09/25/2007 - "This study investigates the use of the optical pharmacokinetic system (OPS) to measure concentrations of the anti-cancer agent motexafin gadolinium (MGd) in mouse tissues noninvasively and nondestructively using elastic-scattering spectroscopy. "
04/01/2006 - "Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers."
06/01/2004 - "The goal of this study is to examine how a mid-treatment MRI impacts the delineation and definition of the boost volume in GBM patients in comparison to the pre-treatment MRI scan, particularly when the tumor-specific agent Motexafin-Gadolinium is used."
04/01/1999 - "A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging."
|3.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/01/2007 - "Motexafin gadolinium injection for the treatment of brain metastases in patients with non-small cell lung cancer."
04/01/2011 - "Multicenter phase II trial of Motexafin gadolinium and pemetrexed for second-line treatment in patients with non-small cell lung cancer."
01/01/2004 - "The first trial, conducted in patients with stage IIIA non-small cell lung cancer, was designed to determine the safety of two different dosing regimens of motexafin gadolinium during preoperative radiotherapy after induction chemotherapy. "
03/15/2009 - "To determine the efficacy of motexafin gadolinium (MGd) in combination with whole brain radiotherapy (WBRT) for the treatment of brain metastases from non-small-cell lung cancer. "
03/15/2009 - "Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial."
|4.||Brain Neoplasms (Brain Tumor)
09/01/2009 - "In the following manuscript, we summarize motexafin gadolinium and its role in brain tumors."
09/01/2009 - "Motexafin gadolinium: a novel radiosensitizer for brain tumors."
06/01/2007 - "Motexafin gadolinium: a novel radiosensitizer for brain tumors."
12/01/2004 - "Motexafin gadolinium: a clinical review of a novel radioenhancer for brain tumors."
01/01/2004 - "In December 2002, Pharmacyclics began a phase III trial of motexafin gadolinium in patients with brain metastases (brain cancer in phase table) from lung cancer in the US, Europe, Canada and Australia. "
|6.||Aminolevulinic Acid (Levulan)
|2.||Photochemotherapy (Photodynamic Therapy)
|3.||Drug Therapy (Chemotherapy)
|5.||Heterologous Transplantation (Xenotransplantation)